This is a working overview of synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-28. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
12(S)-HpETE, 12(R)-HETE, racemic mixtures of these 12-HETEs, and/or 12-oxo-ETE stimulate: a) the directed migration (chemotaxis) of human, rat, and rabbit neutrophils as well as rabbit macrophages; b) human neutrophils to adhere to each other (i.e. aggregate) and in cooperation with tumor necrosis factor alpha or platelet-activating factor, to release their granule-bound enzymes; c) the binding of human vascular epithelial cells to human monocytes; d) DNA synthesis and mitogenesis in the immortalized human keratinocyte cell line HaCaT; and e) when injected in the skin of human volunteers, the extravasation and local accumulation of circulating blood neutrophils and mononuclear cells. These results suggest these metabolites contribute to the inflammation that occurs at sites where they are formed in abnormal amounts such as in human rheumatoid arthritis, inflammatory bowel disease, contact dermatitis, psoriasis, various forms of ichthyosis including congenital ichthyosiform erythroderma, and corneal inflammatory diseases. Since BLT2 appears to mediate the responses of leukocytes to 12(S)-HpETE, 12(S)-HETE, 12(R)-HETE, and 12-oxo-ETE but GPR31 is expressed by various other cells (e.g. vascular endothelium) involved in inflammation, the pro-inflammatory actions of 12-HETE in humans may involve both types of G protein-coupled receptors.
The United States detonated an experimental device in the 1955 Operation Teapot "MET" test which used a plutonium/233U composite pit; its design was based on the plutonium/235U pit from the TX-7E, a prototype Mark 7 nuclear bomb design used in the 1951 Operation Buster-Jangle "Easy" test. Although not an outright fizzle, MET's actual yield of 22 kilotons was sufficiently below the predicted 33 kt that the information gathered was of limited value. The United States conducted several additional weapons tests with 233U for unknown purposes. The Soviet Union detonated its first hydrogen bomb the same year, the RDS-37, which contained a fissile core of 235U and 233U. In 1998, as part of its Pokhran-II tests, India detonated an experimental 233U device of low-yield (0.2 kt) called Shakti V. The B Reactor and others at the Hanford Site optimized for the production of weapons-grade material have been used to manufacture 233U. The United States Atomic Energy Commission used the weapons production reactors at Hanford to breed significant quantities of 233U from thorium for use in both nuclear weapons and for civilian research. Overall the United States is thought to have produced two tons of 233U, of various levels of purity, some with 232U impurity content as low as 6 ppm. The hazards are significant even at 5 parts per million. Implosion nuclear weapons require 232U levels below 50 ppm (above which the 233U is considered "low grade"; cf.
=== African American representation in the media === Crack cocaine hit the streets of the United States in 1985. A decline in legitimate inner-city employment opportunities led some to sell drugs, most notably crack. The unsettled and developing crack markets created a wave of violence in many neighborhoods of the United States. The DEA began lobbying congress on behalf of Reagan's war on drugs initiative by courting media outlets in an attempt to win public support for the war on drugs. Robert Strutman, head of the New York City DEA office recalled, "In order to convince Washington, I needed to make drugs a national issue and quickly. I began lobbying efforts and I used the media. The media was only too willing to cooperate." In June 1986, Newsweek called crack the biggest story since the Vietnam War and Watergate, and in August, Time termed crack "the issue of the year." Stories written about crack featured terms like "welfare queen," "crack babies" and "gangbangers," racially targeted terms. "Welfare queen" and "Predator criminals" were among the most frequently used terms, which had been coined by Reagan during his presidential campaign. The sociologists Craig Reinerman and Harry Levine stated, "Crack was a godsend to the right.... It could not have appeared at a more politically opportune moment."
This is a list of people who disappeared mysteriously during the 1990s or whose deaths or exact circumstances thereof are not substantiated. Many people who disappear end up declared presumed dead and some of these people were possibly subjected to forced disappearance. This list is a general catch-all; for specialty lists, see Lists of people who disappeared.
Sources: en.wikipedia.org
In 1997, the company entered into a co-marketing agreement with Warner–Lambert for Lipitor (atorvastatin), a statin for the treatment of hypercholesterolemia. Although atorvastatin was the fifth statin to be developed, clinical trials showed that atorvastatin caused a more dramatic reduction in low-density lipoprotein pattern C (LDL-C) than the other statin drugs. Upon its patent expiration in 2011, Lipitor was the best-selling drug ever, with approximately $125 billion in sales over 14.5 years.
== Pharmacokinetics in humans == A study was conducted to define the pharmacological response of humans to ractopamine. A single oral dose of 40 mg of ractopamine hydrochloride was given to human volunteers. The drug was rapidly absorbed; the mean blood plasma half-life was around 4 hrs and it was not detected in plasma 24 hrs after dosing. Less than 5% of total ractopamine excreted represented the parent drug, while the urinary metabolites were monoglucuronide and monosulfate conjugates, with ractopamine monosulfate being the major metabolite present. The metabolic fate of ractopamine hydrochloride is similar in the target species (pigs and cattle), laboratory animals, and humans. Besides the pharmacology effect, ractopamine may cause intoxication effect; therefore, any consumption by humans of a meat and/or byproducts of animals that consumed ractopamine with feed for growth stimulation, may result in such clinical effects as tachycardia and other heart rate increases, tremor, headache, muscle spasm, or high arterial blood pressure.
A Possible start codons in NCBI table 1. ATG is most common. The two other start codons listed by table 1 (GTG and TTG) are rare in eukaryotes. Prokaryotes have less strigent start codon requirements; they are described by NCBI table 11. B ^ ^ ^ The historical basis for designating the stop codons as amber, ochre and opal is described in an autobiography by Sydney Brenner and in a historical article by Bob Edgar.
Sources: en.wikipedia.org
=== Complications === GDM poses a risk to the mother and child. This risk is largely related to uncontrolled blood glucose levels and their consequences. The risk increases with higher blood glucose levels. Treatment resulting in better control of these levels can reduce some of the risks of GDM considerably. Having GDM can lead to mental health issues, with the distress added to the pregnancy. Women with gestational diabetes experienced increased anxiety, depression, and stress. Not only does it affect mental health during pregnancy, but it also leads to an increased risk of postpartum depression. The risk is over 4 times greater than a normal pregnancy. It was found that physical activity could decrease the risk of postpartum depression. It is a form of therapy that can help reduce the stress of these mental health issues. The two main risks GDM imposes on the baby are growth abnormalities and chemical imbalances after birth, which may require admission to a neonatal intensive care unit. Infants born to mothers with GDM are at risk of being both large for gestational age (macrosomic) in unmanaged GDM, and small for gestational age and Intrauterine growth retardation in managed GDM. Macrosomia in turn increases the risk of instrumental deliveries (e.g., forceps, ventouse, and caesarean section) or problems during vaginal delivery (such as shoulder dystocia). Macrosomia may affect 12% of normal women compared to 20% of women with GDM.
=== 2013–2015: Top five best and fairest finish then inconsistency === The first intra-club match during the 2013 pre-season saw Melksham break his hand, which required surgery, he managed to return for the NAB Cup, playing his first match in round two. He played the first four matches of the season before he was omitted for the Anzac Day match against Collingwood in round five, he played in the VFL that weekend for Essendon's reserves side in the thirty-five-point win against North Ballarat and was named in the best players, which saw him return to the senior side for the thirty-nine-point win against Greater Western Sydney at Etihad Stadium in round six. He found himself in trouble when he was reported for rough conduct against Jarryd Roughead during the fifty-six-point loss against Hawthorn at Etihad Stadium in round eighteen, he subsequently received a reprimand from the match review panel. An incident during the final round match against Richmond saw him receive a two-match suspension for striking Daniel Jackson. He played twenty-one matches for the year with The Age journalist, Rohan Connolly stating his form had improved from the previous year; this was reflected in his fifth-place finish in the club best and fairest count. He was also rewarded with a two-year contract extension, tying him to the club until the end of the 2015 season.
The Litton detector was developed for sampling the light energy distribution in the rear focal-plane of a spherical lens for sampling geometric relationships and the spectral density distribution of objects recorded on film transparencies. The application of the Litton detector by Salzman et al. provided measurement at 32 small scattering angles between 0° and 30°, and averaging over a broad range of azimuthal angles as the most important angles are the forward angles for static light scattering. By 1980, Bartholi et al. had developed a new approach to measuring the scattering at discrete scattering angles by using an elliptical reflector to permit measurement at 30 polar angles over the range 2.5° ≤ θ ≤ 177.5° with a resolution of 2.1°. The commercialization of multiangle systems began in 1977 when Science Spectrum, Inc. patented a flow-through capillary system for a customized bioassay system developed for the USFDA. The first commercial MALS instrument incorporating 8 discrete detectors was delivered to S.C. Johnson and Son, by Wyatt Technology Company, in 1983, followed in 1984 with the sale of the first 15 detector flow instrument (Dawn-F) to AMOCO. By 1988, a three-dimensional configuration was introduced specifically to measure the scattering properties of single aerosol particles. At about the same time, the underwater device was built to measure the scattered light properties of single phytoplankton. Signals were collected by optical fibers and transmitted to individual photomultipliers.
This is particularly important for heterogeneous cell populations, where overall bulk measurements may mask important cell-to-cell differences in protein synthesis. Other methods are polysome profiling, full-length translating mRNA profiling (RNC-seq), and translating ribosome affinity purification (TRAP-seq). Unlike the transcriptome, the translatome is a more accurate approximation for estimating the expression level of some genes, since the correlation between the proteome and translatome is higher than the correlation between the transcriptome and proteome.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.